The orbital fibroblast: A key player and target for therapy in Graves' ophthalmopathy

Orbit

Volumn 29, Issue 4, 2010, Pages 202-206

  Van Steensel, Leendert ^a   Dik, Willem A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Graves' Ophthalmopathy; Orbital fibroblast; Pathogenesis; PDGF; Therapy

Indexed keywords

DASATINIB; IMATINIB; INTERLEUKIN 6; INTERLEUKIN 8; NILOTINIB; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN RECEPTOR; THYROTROPIN RECEPTOR;

ADIPOCYTE; CELL PROLIFERATION; ENDOCRINE OPHTHALMOPATHY; FIBROBLAST; HUMAN; MACROPHAGE; ORBIT; PATHOGENESIS; PHENOTYPE; REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DRUG DELIVERY SYSTEMS; FEMALE; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOLOGIC FACTORS; MALE; ORBIT; PLATELET-DERIVED GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 77956313716     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.3109/01676831003668443     Document Type: Review

References (32)

1. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003 Dec;24(6):802-835
2. Khoo TK, Bahn RS. Pathogenesis of Graves' ophthal-mopathy: the role of autoantibodies. Thyroid. 2007 Oct;17(10):1013-1018
3. Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid. 2008 Sep;18(9):959-965
4. Eckstein AK, Quadbeck B, Tews S, Mann K, Kruger C, Mohr CH, et al. Thyroid associated ophthalmopathy: evidence for CD4(+) gammadelta T cells; de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression. Br J Ophthalmol. 2004 Jun;88(6):803-808
5. Natt N, Bahn RS. Cytokines in the evolution of Graves' oph-thalmopathy. Autoimmunity. 1997;26(2):129-136
6. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profle in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf). 2003 Mar;58(3):280-287
7. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fbroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003 Jun 15;170(12):6348-6354
8. Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphe-nomenon? J Endocrinol Invest. 2004 Mar;27(3):221-229
9. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fbroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004 Oct;89(10):5076-5080
10. Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simo-netta S, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007 Jan;156(1):33-40.
11. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedus L, Nielsen CH. Treatment of Graves' disease with rituximab specifcally reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009 Mar;130(3):252-258
12. Wynn TA. Cellular and molecular mechanisms of fbrosis. J Pathol. 2008 Jan;214(2):199-210.
13. Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE, Jyonouchi SC, et al. Differentiation of human orbital preadipocyte fbroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab. 1999 Jul;84(7):2557-2562
14. Boschi A, Daumerie C, Spiritus M, Beguin C, Senou M, Yuk-sel D, et al. Quantifcation of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbit-opathy. Br J Ophthalmol. 2005 Jun;89(6):724-729
15. Kumar S, Schiefer R, Coenen MJ, Bahn RS. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fbroblasts. Thyroid. 2010 Jan;20(1): 59-65.
16. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fbroblasts. J Immunol. 2002 Jan 15;168(2):942-950
17. Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1+ and Thy-1-subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002 Feb;32(2):477-485
18. Khoo TK, Coenen MJ, Schiefer AR, Kumar S, Bahn RS. Evidence for enhanced Thy-1 (CD90) expression in orbital fbroblasts of patients with Graves' ophthalmopathy. Thyroid. 2008 Dec;18(12):1291-1296
19. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fbroblast subsets defnes myo-fbroblastic or lipofbroblastic phenotypes. Am J Pathol. 2003 Oct;163(4):1291-1300
20. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fbroblasts. J Clin Endocrinol Metab. 2002 May;87(5):2352-2358
21. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmo-pathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2006 Feb;91(2):614-620
22. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by per-oxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009 May; 94(5):1803-1809.
23. Hwang CJ, Affyan N, Sand D, Naik V, Said J, Pollock SJ, et al. Orbital fbroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperin-duces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci. 2009 May;50(5):2262-2268
24. van Steensel L, Paridaens D, Dingjan G, van Daele P, van Hagen P, Kuijpers R, et al. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fbroblasts in Graves' Ophthalmopathy. Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1002-1007
25. van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PL, van Hagen PM, et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fbroblasts: a potential treatment for Graves' ophthalmopathy. Invest Oph-thalmol Vis Sci. 2009 Jul;50(7):3091-3098
26. Heufelder AE, Bahn RS. Modulation of Graves' orbital fbroblast proliferation by cytokines and glucocorti-coid receptor agonists. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):120-127
27. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fbroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998 Nov 6;273(45):29615-29625
28. Douglas RS, Affyan NF, Hwang CJ, Chong K, Haider U, Richards P, et al. Increased Generation of Fibrocytes in Thyroid-Associated Ophthalmopathy. J Clin Endocrinol Metab. 2009 Nov 6.
29. Keeley EC, Mehrad B, Strieter RM. Fibrocytes: Bringing new insights into mechanisms of infammation and fbrosis. Int J Biochem Cell Biol. 2009 Oct 20.
30. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Bot-stein D, et al. Diversity, topographic differentiation, and positional memory in human fbroblasts. Proc Natl Acad Sci\USA. 2002 Oct 1;99(20):12877-12882
31. Kazim M, Goldberg RA, Smith TJ. Insights into the patho-genesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol. 2002 Mar;120(3):380-386
32. Smith TJ. Unique properties of orbital connective tissue underlie its involvement in Graves' disease. Minerva Endo-crinol. 2003 Sep; 28 (3):213-222